Global health care company Eisai entered into a joint research agreement along with Keio University, with a goal to find new drugs plus therapies for the treatment of dementia.
The Eisai-Keio Innovation Lab for Dementia (tentative name) will be a bottom for industry– academia collaboration within Keio University’s Shinanomachi campus (Shinjuku ward, Tokyo). The lab will be a built-in research site for clinical medicine and basic medication and will be staffed by experienced researchers from both agencies. The Innovation Lab will perform three functions: medical omics analysis, utilizing the latest mass spectroscopy technology; information science, utilizing artificial intelligence (AI) to identify new medication targets; and biological validation, which makes use of induced pluripotent stem cell (iPSC) technology to advance the study of medication target biology.
Keio University prides by itself on unifying basic and clinical science to improve general human health and longevity, with facilities such as the ambitiously called Center for Supercentenarian Medical Research. Keio University has additionally published extensively about its world-class research into human being iPSCs.
“The establishment of this creativity lab allows us to combine Eisai’s accumulated experience of dementia medication discovery such as Aricept ® (donepezil) with Keio University’s supercentenarian medical research and dementia research, mutually boosting our competitive power, and concluding in an amazing opportunity to develop practical applications, ” stated Hideyuki Okano, dean of Keio University School associated with Medicine.
Eisai has a global network associated with research facilities and manufacturing sites, and several research sewerlines, including neuroscience (e. g., neurology and psychiatric medicines), oncology (e. g., oncotherapy and supportive-care treatments), plus vascular/immunological reaction. The company has over 30 years of study into drugs for the treatment of dementia.
“Dementia is one of the major social and medical issues in an getting older society, and Eisai’s mission is to contribute to overcoming this problem, ” said Teiji Kimura, chief discovery officer from the Eisai Neurology Business Group. “Eisai’s strengths are the computational technology, drug discovery, and biomarker research abilities in the field of neurology. Through this Innovation Lab, we can work together with Keio University which has world-class iPSC technology plus expertise in basic medical science and clinical technology, leading to new innovations, and allowing us to get brand new treatments to patients as soon as possible. ”